IP Verse

Novel Methods - EP3076967

EP3076967

INTRA CELLULAR THERAPIES
Application Number
EP14867061A
Filing Date
Dec 3, 2014
Status
Revoked
Jan 12, 2024
Grant Date
Jul 28, 2021
External Links
Slate, Register, Google Patents

Bibliography

The patent EP3076967B1 was granted to Intra Cellular Therapies on Jul 28, 2021 following the initial filing on Dec 3, 2014 under the application number EP14867061A . The current legal status of the patent is Revoked.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

SANDOZApr 27, 2022ADMISSIBLE

Patent Citations (12) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
INTERNATIONAL-SEARCH-REPORTUS2006178362
INTERNATIONAL-SEARCH-REPORTUS3914421
INTERNATIONAL-SEARCH-REPORTWO2011133224
INTERNATIONAL-SEARCH-REPORTWO2013155504
OPPOSITIONUS2006178362
OPPOSITIONUS3914421
OPPOSITIONWO2009145900
OPPOSITIONWO2011133224
OPPOSITIONWO2013155504
OPPOSITIONWO2014145192
SEARCHWO2009145900
SEARCHWO2014145192

Non-Patent Literature (NPL) Citations (22) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
EXAMINATION- KAHN A. ET AL, "Residual symptoms of schiziprenia. What are realistic treatment goals? Lingering symptoms require you to evaluate pharmacotherapy and offer psychosocial interventions", CURRENT PSYCHIATRY, (201703), vol. 16, no. 3, pages 35 - 40-
EXAMINATION- SCHENNACH REBECCA ET AL, "What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial", EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, SPRINGER INTERNATIONAL, BERLIN, DE, vol. 265, no. 2, doi:10.1007/S00406-014-0528-2, ISSN 0940-1334, (20140927), pages 107 - 116, (20140927), XP035456444
OPPOSITION- Aulton E. M., Et Al., "31: Modified-release oral drug delivery", Aulton's Pharmaceutics: The Design and Manufacture of Medicines fourth edition, China, Elsevier, (20130000), pages 500 - 565, XP055920149-
OPPOSITION- Bill Bowman, "Chapter 20: Colloidal Dispersions", Remington Essentials of Pharmaceutics, London, Pharmaceutical Press, (20120000), pages 343 - 370, XP055920161-
OPPOSITION- E. LINDSTROM et al., "Principal Component Analysis of the Swedish Version of the Positive and Negative Syndrome Scale for Schizophrenia", Nord J Psychiatry, (19930000), vol. 47, no. 4, pages 257 - 263, XP055920103-
OPPOSITION- Harvey P. D., Et Al, "Lumateperone Improves Negative Symptoms Related to Emotional Experience (Avolition) in Patient with Schizophrenia", American Society of Clinical Psychopharmacology (ASCP) Annual Meeting, Miami, Florida, (20180601), page 1, XP055920101-
OPPOSITION- KAHN A. et al., "Residual symptoms of schiziprenia. What are realistic treatment goals? Lingering symptoms require you to evaluate pharmacotherapy and offer psychosocial interventions", CURRENT PSYCHIATRY, (20170300), vol. 16, no. 3, pages 35 - 40, XP055920084-
OPPOSITION- KAY S R et al., "THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) FOR SCHIZOPHRENIA", SCHIZOPHRENIA BULLETIN, (19870101), vol. 13, no. 2, ISSN 0586-7614, pages 261 - 276, XP009020866-
OPPOSITION- KAY S R; FISZBEIN A; OPLER L A, "The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia", Schizophrenia Bulletin, (19870000), vol. 13, no. 2, pages 261 - 276, XP009020866-
OPPOSITION- LIEBERMANN et al., "Archival Report : ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial", Biological Psychiatry, (20160000), vol. 79, pages 952 - 961, XP055920094-
OPPOSITION- P.D. HARVEY, "Ziprasidone and Cognition: The Evolving Story", J Clin Psychiatry, (20030000), vol. 64, pages 33 - 39, XP055920113-
OPPOSITION- R. MASS et al., "Psychopathological Syndromes of Schizophrenia: Evaluation of the Dimensional Structure of the Positive and Negative Syndrome Scale", Schizophrenia Bulletin, (20000000), vol. 26, no. 1, pages 167 - 177, XP055920108-
OPPOSITION- Vanover K., Et Al., "A Novel Approach to Address an Unmet Need in the Treatment of Schizophrenia and Depression: Lumateperone, an Innovative Modulator of Dopamine, Serotonin and Glutamate", Intra-Cellular Therapies, (20180531), page 1, XP055920098-
OPPOSITION- ZANG et al., "Alterations of amplitude of low-frequency fluctuation in treatment-resistant versus non-treatment-resistant depression patients", Neuropsychiatric Disease and Treatment, (20190000), vol. 15, pages 2119 - 2128, XP055920090-
OPPOSITION- SCHENNACH REBECCA et al., "What are residual symptoms in schizophrenia spectrum disorder? Clinical description and 1-year persistence within a naturalistic trial", EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE, BERLIN, DE, (20140927), vol. 265, no. 2, ISSN 0940-1334, pages 107 - 116, XP035456444
OPPOSITION- Del-Monte Jonathan, Raffard Stéphane, Salesse Robin N., Marin Ludovic, Schmidt Richard C., Varlet Manuel, Bardy Benoît G., Philippe Boulenger Jean, Christine Gély-Nargeot Marie, Capdevielle Delphine, "Nonverbal expressive behaviour in schizophrenia and social phobia", Psychiatry Research, (20130000), vol. 210, pages 29 - 35, XP028755890
OPPOSITION- Docherty J.P., Baker R.A., Eudicone J., Mathew S., Marcus R.N., Mcquade R.D., Mankoski R., "Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia", Schizophrenia Research, (20100000), vol. 120, pages 199 - 203, XP027104546
OPPOSITION- T LEE, "Novel, highly potent, selective 5-HT2A/D2 receptor antagonists as potential atypical antipsychotics", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (20030201), vol. 13, no. 4, ISSN 0960-894X, pages 767 - 770, XP055005306
OPPOSITION- LAURA LAMMERS et al., "Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada", BMC PSYCHIATRY, LONDON, GB, (20130530), vol. 13, no. 1, ISSN 1471-244X, page 155, XP021152119
SEARCH- KAY S R ET AL, "THE POSITIVE AND NEGATIVE SYNDROME SCALE (PANSS) FOR SCHIZOPHRENIA", SCHIZOPHRENIA BULLETIN, OXFORD UNIVERSITY PRESS, (19870101), vol. 13, no. 2, ISSN 0586-7614, pages 261 - 276, XP009020866 [AD] 1-21 * the whole document *-
SEARCH- T LEE, "Novel, highly potent, selective 5-HT2A/D2 receptor antagonists as potential atypical antipsychotics", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, (20030201), vol. 13, no. 4, doi:10.1016/S0960-894X(02)01028-4, ISSN 0960-894X, pages 767 - 770, XP055005306 [A] 1-17 * the whole document * * table 2 *
SEARCH- LAURA LAMMERS ET AL, "Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada", BMC PSYCHIATRY, BIOMED CENTRAL, LONDON, GB, (20130530), vol. 13, no. 1, doi:10.1186/1471-244X-13-155, ISSN 1471-244X, page 155, XP021152119 [A] 1-21 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents